Drugs / Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine
Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine
also known as
Pentacel
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03673462 Background | Sep 2018 → Mar 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03673462 ↗ |
| Known as | Pentacel | “along with Pentacel® (DTaP-IPV/Hib vaccine) at 2, 4, and 6 months of age” NCT03673462 ↗ |
| Modality | Vaccine | “Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine” NCT03673462 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT03673462 ↗ |